Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement

Stock Track

May 20

Roivant Sciences Ltd. (ROIV) shares surged 9.89% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.

The biopharmaceutical company reported a significant swing to profitability, with net income attributable to shareholders reaching $302.99 million for the quarter, compared to a loss a year earlier. This unexpected profit was primarily driven by a $770.24 million gain from a litigation settlement with Moderna, which contributed to income from operations of $415.24 million, dramatically beating analyst estimates of a $310.4 million loss.

Beyond the one-time legal gain, Roivant provided a positive business update, reiterating its expectation to launch brepocitinib in dermatomyositis by the end of September 2026 and anticipating key clinical trial data readouts in the second half of the year. The company also reported a strong cash position of $4.3 billion, which it stated supports its runway into profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1120015285"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120015285\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120015285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120015285","market":"nz","top_or_hot":-1,"title":"Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement","media":"Stock Track","content":"<p>Roivant Sciences Ltd. (ROIV) shares surged 9.89% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported a significant swing to profitability, with net income attributable to shareholders reaching $302.99 million for the quarter, compared to a loss a year earlier. This unexpected profit was primarily driven by a $770.24 million gain from a litigation settlement with Moderna, which contributed to income from operations of $415.24 million, dramatically beating analyst estimates of a $310.4 million loss.</p><p>Beyond the one-time legal gain, Roivant provided a positive business update, reiterating its expectation to launch brepocitinib in dermatomyositis by the end of September 2026 and anticipating key clinical trial data readouts in the second half of the year. The company also reported a strong cash position of $4.3 billion, which it stated supports its runway into profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-20 19:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Roivant Sciences Ltd. (ROIV) shares surged 9.89% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported a significant swing to profitability, with net income attributable to shareholders reaching $302.99 million for the quarter, compared to a loss a year earlier. This unexpected profit was primarily driven by a $770.24 million gain from a litigation settlement with Moderna, which contributed to income from operations of $415.24 million, dramatically beating analyst estimates of a $310.4 million loss.</p><p>Beyond the one-time legal gain, Roivant provided a positive business update, reiterating its expectation to launch brepocitinib in dermatomyositis by the end of September 2026 and anticipating key clinical trial data readouts in the second half of the year. The company also reported a strong cash position of $4.3 billion, which it stated supports its runway into profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1120015285","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120015285","pubTimestamp":1779275928,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Roivant Sciences Ltd. (ROIV) shares surged 9.89% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.The biopharmaceutical company reported a significant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"个股追踪|Roivant Sciences盘前大涨9.89%Moderna诉讼和解意外获得Q4盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"Roivant Sciences Ltd. (ROIV) shares surged 9.89% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.The biopharmaceutical company reported a significant swing to profitability, with net income attributable to shareholders reaching $302.99 million for the quarter, compared to a loss a year earlier. This unexpected profit was primarily driven by a $770.24 million gain from a litigation settlement with Moderna, which contributed to income from operations of $415.24 million, dramatically beating analyst estimates of a $310.4 million loss.Beyond the one-time legal gain, Roivant provided a positive business update, reiterating its expectation to launch brepocitinib in dermatomyositis by the end of September 2026 and anticipating key clinical trial data readouts in the second half of the year. The company also reported a strong cash position of $4.3 billion, which it stated supports its runway into profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}